Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

Simple item page
dc.contributor.authorHicks, J. Kevin
dc.contributor.authorSangkuhl, Katrin
dc.contributor.authorSwen, Jesse J.
dc.contributor.authorEllingrod, Vicki L.
dc.contributor.authorMüller, Daniel J.
dc.contributor.authorShimoda, Kazutaka
dc.contributor.authorBishop, Jeffrey R.
dc.contributor.authorKharasch, Evan D.
dc.contributor.authorSkaar, Todd C.
dc.contributor.authorGaedigk, Andrea
dc.contributor.authorDunnenberger, Henry M.
dc.contributor.authorKlein, Teri E.
dc.contributor.authorCaudle, Kelly E.
dc.contributor.authorStingl, Julia C.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2019-01-02T15:14:07Z
dc.date.available2019-01-02T15:14:07Z
dc.date.issued2017-07
dc.description.abstractCYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, doxepin, imipramine, and trimipramine). Evidence is presented for CYP2D6 and CYP2C19 genotype-directed dosing of TCAs. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationHicks, J. K., Sangkuhl, K., Swen, J. J., Ellingrod, V. L., Müller, D. J., Shimoda, K., Bishop, J. R., Kharasch, E. D., Skaar, T. C., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Caudle, K. E., … Stingl, J. C. (2017). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clinical pharmacology and therapeutics, 102(1), 37-44.en_US
dc.identifier.urihttps://hdl.handle.net/1805/18060
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/cpt.597en_US
dc.relation.journalClinical pharmacology and therapeuticsen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectCYP2D6en_US
dc.subjectCYP2C19en_US
dc.subjectPharmacogeneticsen_US
dc.subjectTricyclic antidepressantsen_US
dc.subjectAmitriptylineen_US
dc.subjectClomipramineen_US
dc.subjectDesipramineen_US
dc.subjectDoxepinen_US
dc.subjectImipramineen_US
dc.subjectNortriptylineen_US
dc.subjectTrimipramineen_US
dc.titleClinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nihms836790.pdf
Size:
165.76 KB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works
Todd Skaar